Clinical Trials
22 trialsNCT06245746 2025-03-21
UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Recruiting
NCT04187898 2024-09-19
Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
Spectrum Pharmaceuticals, Inc
Phase 1 Completed
NCT00020371 2024-03-04
BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy
National Cancer Institute (NCI)
Phase 1 Completed
NCT02527746 2024-02-23
Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology
Phase 1 Completed
NCT05622058 2023-02-27
A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer
Aileron Therapeutics, Inc.
Phase 1 Terminated
NCT00002866 2020-04-01
Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 1 Completed
NCT01629082 2019-12-17
Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01484015 2018-07-18
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
Wake Forest University Health Sciences
Phase 1 Completed
NCT02725606 2017-08-18
Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer
Jiangsu T-Mab Biopharma Co.,Ltd
Phase 1 Unknown
NCT03246009 2017-08-11
Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients
Tianjin SinoBiotech Ltd.
Phase 1 Completed
NCT02700360 2016-03-15
Evaluation of the Food Effect on the Safety, Tolerability, PK of EC-18 After Oral Administration in Healthy Volunteers
Enzychem Lifesciences Corporation
Phase 1 Completed
NCT02532712 2016-01-27
Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers
Enzychem Lifesciences Corporation
Phase 1 Completed
NCT01164215 2015-10-09
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT01919710 2015-06-03
Safety and Efficacy Studies of rHSA/GCSF Fusion Protein For Injection to Treat Neutropenia
Tianjin SinoBiotech Ltd.
Phase 1 Completed
NCT00352300 2014-12-31
Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer
GOG Foundation
Phase 1 Completed
NCT00003597 2014-07-24
Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors
Children's Oncology Group
Phase 1 Completed
NCT00002759 2013-02-05
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00520325 2012-09-05
A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia
Enzon Pharmaceuticals, Inc.
Phase 1 Withdrawn
NCT00886496 2012-06-20
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia
Enzon Pharmaceuticals, Inc.
Phase 1 Withdrawn
NCT00005787 2012-06-01
Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma
Northwestern University
Phase 1 Terminated
NCT00002693 2011-08-03
Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia
Mayo Clinic
Phase 1 Completed
NCT00001533 2006-07-17
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine
National Institutes of Health Clinical Center (CC)
Phase 1 Completed